Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

-8.0%

Nov 6 3:46 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	4/30/2014 8:08:07 AM
	of 13111

Report: Ipilimumab Use May Be Associated With Development Of Myasthenia Gravis. Medscape (4/30, Mulcahy) reports, “The use of ipilimumab (Yervoy, Bristol-Myers Squibb) for the treatment of melanoma has been associated with the development of myasthenia gravis, an autoimmune neuromuscular disorder that manifests as muscle weakness and fatigue, according to a report published...in the Journal of Clinical Oncology.” This “report, which describes 2 cases, is the first in the medical literature of ipilimumab-associated myasthenia gravis, according to the authors,” who “also observe that other severe neurologic disorders following ipilimumab have been observed previously, including acute inflammatory demyelination polyneuropathy and an ascending motor paralysis, which shares features of both myasthenia gravis and acute inflammatory demyelination polyneuropathy.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next